NEW YORK – Syapse said on Thursday that it has landed $30 million in new equity investments. Revelation Alpine led the round, with participation from previous investors Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance, Safeguard Scientifics, and Social Capital.
As a result of the investment, Revelation Alpine Managing Partner Zack Scott has been named to the Syapse board of directors.
Syapse, a San Francisco-based maker of software to support precision oncology care and drug discovery, did not name this round of venture capital, but the company raised $30 million in a Series D round in November 2017. The Stanford University spinoff has landed at least $98 million in venture investments since its inception in 2014.
The firm works with life science companies to provide analytics via "real-world" clinical, molecular, and outcomes data to support R&D, clinical trial matching, regulatory filings, post-approval monitoring, and treatment decisions.
"We are in an unprecedented time that has further highlighted the urgent need for new tools in the delivery of care to patients facing challenging and chronic health conditions, including cancer," Henry Ford Medical Group CEO Steve Kalkanis said in a statement. "This financing is another step forward in support of our collaboration with Syapse to advance the use of real-world data and precision medicine in improving outcomes for patients."
Detroit-based Henry Ford Health System launched its precision oncology program in 2016 with the help of Syapse.